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Abstract 
Wilms tumor and nephroblastomatosis are associated with syndromic conditions including 
hemihyperplasia. Hemihyperplasia is genetically heterogeneous and may be the result of 
genomic abnormalities seen in Beckwith-Wiedemann syndrome, mosaic chromosome or 
genomic abnormalities, or somatic point mutations. Somatic missense mutations affecting the 
PI3K-AKT-MTOR pathway result in segmental overgrowth and are present in numerous benign 
and malignant tumors. Here we report a fourth patient with asymmetric overgrowth due to a 
somatic PIK3CA mutation who had nephroblastomatosis or Wilms tumor. Similar to two of 
three reported patients with a somatic PIK3CA mutation and renal tumors, he shared a PIK3CA 
mutation affecting codon 1047, presented at birth with asymmetric overgrowth and had 
fibroadipose overgrowth. Codon 1047 is most commonly affected by somatic mutations in 
PIK3CA-related overgrowth spectrum (PROS).  While the fibroadipose overgrowth phenotype 
appears to be common in individuals with PIK3CA mutations at codon 1047, individuals with a 
clinical diagnosis of Klippel-Trenaunay syndrome or isolated lymphatic malformation also had 
mutations affecting this amino acid. Screening for Wilms tumor in individuals with PROS-related 
hemihyperplasia may be considered and, until the natural history is fully elucidated in larger 
cohort studies, may follow guidelines for Beckwith-Wiedemann syndrome or isolated 
hemihyperplasia. It is not known if the specific PIK3CA mutation, the mosaic distribution or the 
clinical presentation affect the Wilms tumor or nephroblastomatosis risk in individuals with 
PROS. 
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INTRODUCTION 
Overgrowth syndromes can be associated with an increased risk for malignant tumors. 
Beckwith-Wiedemann syndrome is a typical example of this association [Shuman et al., 2000]. 
Asymmetric overgrowth or hemihyperplasia occurs in patients with Beckwith-Wiedemann 
syndrome (MIM 130650), but can be an isolated finding. An increased risk for malignant 
tumors, particularly for Wilms tumor, has been documented in individuals with Beckwith-
Wiedemann syndrome or isolated hemihyperplasia (MIM 235000). Hemihyperplasia is 
genetically heterogeneous, including genomic abnormalities seen in Beckwith-Wiedemann 
syndrome, as well as mosaic chromosome or genomic abnormalities and somatic point 
mutations. Somatic mutations affecting the PI3K-AKT-MTOR pathway result in segmental 
overgrowth and other physical findings. Similarly, somatic mutations affecting the PI3K-AKT 
pathway are present in numerous benign and malignant tumors (see [Samuels and Waldman, 
2010] for review). In individuals presenting in early childhood with segmental overgrowth or 
other findings related to somatic mutations in the PI3K-AKT-MTOR pathway, the mutation 
inherently occurred during an early developmental stage and may result in an increased 
lifetime risk for neoplasias driven by mutations in this pathway. Detailed understanding of the 
clinical phenotypes related to these mutations [Lee et al., 2012; Lindhurst et al., 2012; Poduri et 
al., 2012; Rios et al., 2012; Riviere et al., 2012; Kurek et al., 2012; Mirzaa et al., 2013; Keppler-
Noreuil et al., 2014; Keppler-Noreuil et al., 2015] may allow for delineation of the associated 
cancer risks based on the specific mutation and the affected cell lineages. Here we report two 
individuals with somatic mosaicism for the most common PIK3CA mutations, c.3140A>G 
p.His1047Arg and c.3140A>T p.His1047Leu, and a history of Wilms tumor or 
Page 4 of 34
John Wiley & Sons, Inc.
American Journal of Medical Genetics: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
nephroblastomatosis and compare their presentations to the two other reported individuals 
with a somatic PIK3CA mutation and Wilms tumor or nephroblastomatosis. 
MATERIALS AND METHODS 
Patient 1 was evaluated clinically and testing for overgrowth was completed clinically. Informed 
signed consent was obtained, and clinical data, clinical photographs and molecular results were 
reviewed. Patient 2 was enrolled in a somatic overgrowth study and evaluated at the National 
Institutes of Health after obtaining informed consent. She was previously reported as patient 23 
in Keppler-Noreuil et al. [2014]. Updated history, exam and testing were obtained for this 
report. 
 We reviewed the literature and reviewed cohort data in order to gather information on 
the frequency of Wilms tumor and nephroblastomatosis in individuals with somatic PIK3CA 
mutations. 
Cambridge cohort 
This study was approved by the UK National Research Ethics Committee. Written informed 
consent was obtained from all participants or their parents. Genomic DNA was extracted from 
lesions using standard procedures and imaging was conducted as part of routine clinical care. 
Somatic PIK3CA mutations were detected in affected tissues using Next Generation Sequencing 
with preceding target enrichment. Equipment and materials were purchased from Life 
Technologies, Thermo-Fisher Scientific using a custom-designed primer pool which provides 
coverage of all coding regions of PIK3CA and related genes (primer sequences available on 
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request). The mean depth of coverage for sequencing was 2000X. Mutations were verified to be 
disease-causing on the basis of; i) finding the same mutation in additional probands with a 
similar phenotype ii) published experimental data confirming activation of downstream 
effectors of PI3K, and/or iii) the presence of the mutation in the catalogue of somatic mutations 
in cancer (COSMIC) [Forbes et al., 2015]. 
Clinical Reports 
Patient 1 
The proband was born vaginally at 35 weeks of gestation after a pregnancy complicated by 
maternal urinary tract infection and possible polyhydramnios on prenatal ultrasound. His G2P1-
>2 mother was 22 years old and his father was 26 years old. His African American parents were 
non consanguineous. One maternal and three paternal half-sibs were in good health. Birth 
weight was 2.47 kg (25-50
th
 centile for gestational age) and length 48.3 cm 75
th
 centile for 
gestational age). OFC was not documented. Asymmetric overgrowth with right thigh 
enlargement was present from birth and resulted in evaluations for hemihyperplasia. At age 5 
months, physical examination was remarkable for bilateral supranumerary nipples, increased 
girth in the right leg compared to the left, and a hypopigmented lesion on the lower abdomen. 
 A small left kidney with enlargement of the right kidney was noted on ultrasound at age 
5 weeks. Renal ultrasound at age 9 months showed three well defined hypoechoic avascular 
masses in the right kidney measuring 1.3x1.1x1.4 cm, 1.6x1.4x1.4 cm and 1.7x1.3x1.4 cm, 
respectively (Figure 1a). The lesions were confirmed by CT study (Figure 1b, c), which 
incidentally showed a marked asymmetry of the paravertebral and pelvic musculature with all 
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muscles on the right larger than the on the left. The MRI imaging similarly demonstrated the 
renal masses (Figure 1d). Wilms tumor was diagnosed and chemotherapy administered in an 
effort to allow surgery later with preservation of kidney function. This decision was in 
consideration of his atrophic left kidney, which contributed 23% to total renal function. A 
subsequent CT scan (Fig. 1c) demonstrated the tumors’ sizes to be unchanged or increased, and 
a needle biopsy was performed at age 10 months. In this post-treatment biopsy the pathology 
diagnosis was a nephrogenic lesion, it was impossible to differentiate between nephrogenic 
rests and Wilms tumor. Chemotherapy was completed as planned. The lesions responded to 
therapy and were monitored through imaging studies. Surgical resection was not performed.
 A soft lipomatous mass in the right paraspinal region above the iliac crest was first 
documented at age 2 years. An MRI at age 7 years showed a 2.8x2.8x10 cm focus of abnormal 
signal intensity within the right vastus lateralis muscle. An MRI at age 7 10/12 years showed the 
same stable lesion and regions of post contrast enhancement in the right iliac muscle (Figure 2, 
a-d).  Fatty lobules in the left paraspinal soft tissue at L3-L5 appeared stable compared to 
previous studies and did not encroach on the neural foramina. The right L3 root was anteriorly 
displaced, implying fatty infiltration in the right L3-L4 neural foramen. Stable fatty prominence 
in the right L5-S1 neural foramen was noted. Due to discomfort, the paraspinal intramuscular 
lipoma was surgically removed at age 8 years. Pathology showed mature adipose tissue 
encompassing skeletal muscle, consistent with an intramuscular lipoma. 
 The size discrepancy of his legs persisted. An enhancing lesion in the right psoas was 
seen on MRI (Figure 2b) and a needle biopsy results obtained at age 4 years suggested an 
inflammatory myopathy. The entire right leg was larger than the left in diameter and the right 
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femur was approximately 1 cm longer than the left at age 7 years. The patient had a mild gait 
abnormality owing to the asymmetric overgrowth. Persistent thigh pain was the indication for 
an MRI showing signal abnormalities in the vastus lateralis and peroneus brevis (Figure 2 c, d), 
but open muscle biopsy at age 8 years showed skeletal muscle without significant pathology. 
 His motor and speech development were age appropriate with walking independently 
at age 1 year and single words around the same time. At age 7 years his cognitive development 
was age appropriate and he attended a typical classroom setting. His height at age 7 years was 
127 cm (50
th
-75
th
 centile), weight 33.7 kg (>97
th
 centile, Z-score 1.8) and OFC 52.5 cm (50
th
-75
th
 
centile). His facial features were symmetric and non dysmorphic. A large mass was visible in the 
right paraspinal region (Figure 3a), and the leg size discrepancy was striking (Figure 3b, c).  
Molecular Laboratory Study Results 
 An overgrowth panel was performed clinically on a next generation platform at the 
University of Pennsylvania. Testing included site-specific regions for AKT1, AKT2, AKT3, GNAQ, 
MTOR, PIK3CA and PIKR2; in addition the coding and flanking intronic boundaries for CDKN1C 
were covered. 
 DNA samples derived from a frozen psoas muscle tissue contained a mosaic 
heterozygous (12.9-15.7%) PIK3CA mutation, c.3140A>G, in exon 20, predicting a p.His1047Arg 
amino acid substitution. The same mutation was present as mosaic heterozygote (21.4-24.8%) 
in a DNA sample from a tissue block of the right thigh mass. Blood sample derived DNA did not 
show the mutation with a confidence score of 99.99%, leading to the conclusion that the 
mutation occurred somatically.  
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 Additional tests performed with non-diagnostic results included methylation-sensitive 
multiplex ligation-dependent probe amplification for large deletions, duplications and/or 
methylation abnormalities in the IC1 (H19) and IC2 (LIT1) critical regions on 11p15 associated 
with Beckwith-Wiedemann syndrome. 
Patient 2 
This individual was originally reported as patient 23 in Keppler-Noreuil et al. [2014] and clinical 
information was updated at age 10 years. The proposita was born at 38 weeks’ gestation by 
induced vaginal delivery after a pregnancy complicated by abnormal prenatal ultrasounds 
revealing “webbed toes” on her right foot and “white spots” on her heart.  Her G1P0- 1 mother 
was 21 years and her father was 26 years old. Her African American parents were 
nonconsanguinous and subsequently had a healthy son. Birth weight was 2.95 kg (10-25
th
 
centile) and length 49.5 kg (50
th
 centile). Her right leg and foot, including her toes were noted 
to be enlarged, and she had hyperpigmentation of her neck and waist.  
At age 2 years, she was found on renal ultrasound imaging to have bilateral hypodense 
renal lesions. She was diagnosed with Wilms tumor. She was treated with 4 months of 
chemotherapy with vincristine, actinomycin, and adriamycin followed by bilateral partial 
nephrectomies. Pathology from the nephrectomies showed adenomatous nephrogenic rests. 
Her renal function has been normal. At age 10 years, abdominal ultrasound showed stable size 
asymmetry of the kidneys with no change in the moderate hydronephrosis involving the right 
kidney; parenchymal thinning with increased cortical echogenicity of the right kidney, and 
normal corticomedullary differentiation of the left kidney with an unchanged nephrogenic rest. 
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She has had progressive overgrowth of her right leg and foot with leg length 
discrepancy. She has undergone multiple orthopedic surgeries including right foot Boyd 
amputation at age 2 years and epiphysiodesis of the right femur and hemiepiphysiodesis of the 
right tibia at age 4 years. An MRI scan of her lower extremities at 6 years showed diffuse multi-
compartmental lipomatosis of the lower extremities with muscular infiltration, right greater 
than left with right buttock and leg enlargement and muscle atrophy. Right patellar dislocation 
was present associated with the intra-articular lipomatosis. Liposuction of her right leg was 
performed at age 6 years, and debulking of her right knee at 7 years. She had eight-plate 
removal from the right lateral proximal tibia, medial distal femur and lateral distal femur at 7 
years. She underwent laparoscopic surgery to remove excess subcutaneous fat from the right 
side of her abdomen at age 8 years.   
 Her motor and speech development were apparently normal. She crawled at 6 months, 
walked at 10 months, drank from a cup at 11 month, spoke in 2 word sentences at 12 months, 
toilet trained at 14 months, and was riding a 2 wheel bike at 8 years. She was in a regular class 
setting with additional help in math. She was diagnosed with attention deficit disorder at age 9 
years.  
On examination at 10 years, her height was 139. 2 cm (50-75
th
 centile), weight 45.4 kg 
(90-97
th
 centile) and OFC 54.2 cm (85
th
 centile). Tanner III breast development was noted. She 
had marked increased, asymmetric enlargement of the right leg and right buttock since her 
initial examination, and a right flank pigmented nevus extending from her waist to her pelvis 
bilaterally. She had soft tissue overgrowth of her left lower and right abdomen and 
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enlargement of her left labia majora. She ambulated with a right Syme prosthesis. Fat tissue 
appeared reduced at the arms, upper torso, and face with prominent muscles and vasculature. 
Thigh circumference was right 61 cm, left 38.8 cm; calf circumference: right 37.5 cm, left 25.2 
cm. Feet length: right amputated, left 24.6 cm. Right hip was lower than the left. Her left great 
toe was enlarged and laterally deviated (Figure  4,a-d).  
Molecular Laboratory Study Results 
 Molecular analysis consisted of candidate mutation analysis for somatic mutations in 
PIK3CA using a custom PCR restriction assay as described in Lindhurst et al. [2012] for the 
c.3140A>T p.His1047Leu mutation. This mutation was found in adipose and skin samples from 
the left leg at the level of 3-4%, with negative results from peripheral blood.  
 PTEN mutation analysis was normal.  
RESULTS 
Literature Review and Cohort Data  
Literature review revealed two reports including individuals with a somatic PIK3CA mutation 
and Wilms tumor [Kurek et al., 2012; Luks et al., 2015] (Table I). Keppler-Noreuil et al. [2014] 
reviewed the clinical and natural history of PIK3CA related overgrowth spectrum in a cohort of 
35 individuals (Table II), including one reported here with updated history and findings as 
Patient 2. Further, two patients with Wilms tumor and megalencephaly-capillary malformation 
(MCAP) (602501) syndrome were reported prior to the identification of the molecular basis of 
MCAP [Lapunzina et al., 2004; Wright et al., 2009]. 
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In a combined cohort of 159 individuals with somatic mutations in PIK3CA from the 
Seattle Children’s Research Institute and the University of Cambridge, UK, no individual was 
identified with Wilms tumor or nephroblastomatosis (Table II). However, these individuals had 
a broad spectrum of clinical phenotypes, including CLOVES syndrome (612918), MCAP, 
fibroadipose overgrowth and isolated hemihyperplasia or macrodactyly. It is important to note 
that longitudinal follow-up data are not available on all individuals and formalized tumor 
screening by abdominal imaging has not been performed on all. The individuals from the UK 
ranged in age from one to 57 years (mean of 16 years), and 45 individuals have had formalized 
screening with abdominal imaging (ultrasound, MRI, CT scan). Overlap of the Cambridge cohort 
with that reported by Keppler-Noreuil et al. [2014] is noted in Table II. 
DISCUSSION 
The two patients described here were diagnosed with renal masses at 9 months and 2 years of 
age, respectively. Imaging studies in both identified hypodense masses in the kidneys 
suggestive of Wilms tumor. In the first patient, pathology from needle biopsy performed after 
treatment was indeterminate regarding the diagnosis of Wilms tumor versus nephrogenic rests. 
In the second patient, pathology showed adenomatous nephrogenic rests. Both patients were 
treated with chemotherapy, and their follow up studies have been stable. Very few patients 
with hemihyperplasia due to a somatic PIK3CA mutation and Wilms tumor or 
nephroblastomatosis have been reported (Table I). Nephrogenic rests or nephroblastomatosis 
refer to foci of embryonal cells persisting beyond 36 weeks of gestation and capable of 
developing into nephroblastomas (Wilms tumor) [Murphy et al., 2004]. These are found in 
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approximately 1% of infant kidneys at autopsy and are associated with an increased risk of 
Wilms tumor [Lonergan et al., 1998]. Nephroblastomatosis is associated with syndromes 
including Beckwith-Wiedemann syndrome, isolated hemihyperplasia, chromosomal 
abnormalities and aniridia [Scott et al., 2006a]. These precursors of Wilms tumor are 
encountered in 25-40% of patients with Wilms tumors. They are often considered a spectrum 
lesion and, like in Patient 1 reported here, cannot always be distinguished. Perilobar 
nephroblastomatosis is typically treated with chemotherapeuty, as was done in Patient 1. 
Kurek et al. [2012] described a female with a clinical diagnosis of CLOVES syndrome and 
a history of Wilms tumor. She had lipomatous overgrowth of the trunk and limbs, with wide 
feet and polydactyly in addition to striking overgrowth of both legs. This patient was mosaic for 
the PIK3CA p.His1047Arg mutation in her legs, but negative for the mutation in a saliva-derived 
DNA sample. Another individual with CLOVES and Wilms tumor was mosaic for the PIK3CA 
p.Asn345Lys mutation and limited clinical information was available (Table I) [Luks et al., 2015]. 
Neither the individuals reported here nor the patient in Kurek et al. [2012] had 
megalencephaly. This is noteworthy because the phenotypic spectrum associated with PIK3CA 
mutations encompasses MCAP syndrome, a clinically distinct disorder manifesting 
predominantly with severe brain overgrowth, and milder body overgrowth than other PIK3CA-
related disorders [Mirzaa et al., 2013]. In a series of 12 patients with MCAP, one had a Wilms 
tumor [Wright et al., 2009]. This 4-year-old male patient had lipomas and a 
dermatomyofibroma. He did not show a PTEN mutation, no other testing was reported [Wright 
et al., 2009]. Another patient with MCAP and Wilms tumor has been reported [patient 2, 
Lapunzina et al., 2004]. This 10 month old girl had megalencephaly, hydrocephalus, cutaneous 
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vascular malformations, joint hyperlaxity, asymmetry and 2-3 toe syndactyly [Lapunzina et al., 
2004]. We are not aware whether this patient has been tested for PIK3CA mutations.  
Somatic PIK3CA Mutation Associated Phenotypes 
Phenotypes associated with somatic PIK3CA mutations are extremely variable, depending upon 
the timing and location of their postzygotic occurrence and the effect of the specific amino acid 
on the protein product. This phenotypic spectrum is now referred to as PIK3CA-Related 
Overgrowth Spectrum (PROS) [Mirzaa et al., 2013; Keppler-Noreuil et al., 2014] and 
encompasses a number of originally clinically defined conditions. The MCAP syndrome was 
previously known as macrocephaly- cutis marmorata teleanciectasia congenita or 
macrocephaly-cutis marmorata and is primarily distinguished by brain overgrowth 
(megalencephaly or hemimegalencephaly) with associated neurologic complications 
(hydrocephalus, Chiari malformation), cutaneous capillary malformations with focal or 
generalized somatic overgrowth and syndactyly or polydactyly, as well as variable connective 
tissue dysplasia [for review see Mirzaa et al., 2013]. The CLOVE syndrome is defined by 
congenital lipomatous overgrowth, vascular malformations and epidermal nevi [Sapp et al., 
2007] and shows significant overlap with fibroadipose hyperplasia. The acronym was extended 
to CLOVES in order to account for skeletal anomalies, scoliosis, spinal anomalies and seizures 
[Alomari 2009]. The CLOVES syndrome may be differentiated from MCAP by the severity of 
somatic overgrowth with characteristic overgrowth of lipomatous tissue and high risk of 
lymphatic and vascular malformations in the former; whereas brain overgrowth predominates 
in MCAP and somatic manifestations, while present, are typically milder than in CLOVES 
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syndrome. Skeletal anomalies including scoliosis and macrodactyly may be more prominent in 
CLOVES syndrome, but polydactyly and syndactyly occur in both syndromes. Individuals having 
overlapping findings of both syndromes are increasingly recognized. Overlap of phenotypic 
findings between CLOVES syndrome and MCAP is exemplified by the extensive cutaneous 
involvement of a truncal vascular malformation in Patient 3 reported by Sapp et al., [2007] and 
the individual reported by Gucev et al. [2008], who had features of CLOVES syndrome and 
hemimegalencephaly. Vascular malformations affecting the skin in combination with focal 
overgrowth are characteristic for Klippel-Trenaunay syndrome, and PIK3CA mutations were 
found in 3/15 patients clinically diagnosed with Klippel-Trenaunay syndrome [Kurek et al., 
2012]. In the majority of patients with Klippel-Trenaunay syndrome, isolated lymphatic 
malformation or a combination of findings including fibro-adipose vascular anomalies, 
mutations in PIK3CA were identified [Luks et al., 2015]. A wide range of unusual presentations 
has been described in case reports, including unilateral hand muscle overgrowth [Castiglioni et 
al., 2014], segmental overgrowth syndrome [Rasmussen et al., 2014] and mesenteric 
lipomatosis [Cohen et al., 2014]. The most common mutation is a postzygotic change affecting 
amino acid 1047, with p.His1047Arg in 19 and p.His1047Leu in 8 of 35 individuals reviewed by 
Keppler-Noreuil et al. [2014] (Table II). While the CLOVES syndrome or fibroadipose hyperplasia 
phenotype appears to be common in individuals with a missense mutation at codon 1047, 
individuals with a clinical diagnosis of Klippel-Trenaunay syndrome or isolated lymphatic 
malformation [Kurek et al., 2012; Luks et al., 2015] also had a mutation affecting this amino 
acid. Keppler-Noreuil et al. [2014] differentiated between mutations at p.His1047, which affect 
the catalytic domain of the protein product, and multiple other changes in the coiled domain 
Page 15 of 34
John Wiley & Sons, Inc.
American Journal of Medical Genetics: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
and concluded that the majority of patients with CLOVES syndrome had mutations in the latter. 
While this was statistically significant within their cohort, there were exceptions even within 
their relatively small cohort. 
Somatic PIK3CA Mutation Associated Malignancies and Wilms Tumor 
The catalytic subunit of phosphatidylinositol-3-kinase (PI3K) is somatically mutated in many 
cancers including colorectal, ovarian, breast, hepatocellular carcinomas and glioblastomas. 
These PIK3CA mutations are located mostly at hotspots within the kinase domain (encoded by 
exon 20), and result in gain-of-function implicated in oncogenicity [Samuels et al., 2004; 
Ikenoue et al., 2005; Kang et al., 2005]. However, isolated Wilms tumor has not previously been 
reported in association with somatic PIK3CA mutations. The risk of tumorigenesis, including 
Wilms tumor, in patients with isolated hemihyperplasia ranges from 3.3-6% [Hoyme et al., 
1998; Lapunzina 2005; Clericuzio and Martin, 2009]. Wilms tumor has been reported in four 
individuals with phenotypes associated with somatic PIK3CA mutations, including the two 
described here.  
Wilms Tumor Screening Recommendations 
Screening has been recommended for young children with syndromic conditions encompassing 
an increased risk for Wilms tumor, most classically Beckwith-Wiedemann syndrome [Beckwith 
1998; Choyke et al., 1999; Clericuzio and Martin, 2009]. Based on the perceived difference in 
the tumor risk ranging from high in isolated hemihyperplasia to mild or moderate in Klippel-
Trenaunay and macrocephaly- capillary malformation syndrome[Table XVIII in Lapunzina 2005], 
varying recommendations for tumor screening have been proposed [Lapunzina 2005]. 
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Lapunzina [Table V in Lapunzina 2005] reviewed the screening guidelines for multiple 
overgrowth syndromes and as expected, the abdominal ultrasound recommendations were 
identical for isolated hemihyperplasia and Beckwith-Wiedemann syndrome with screening 
every 3 months until age 4 years, every 6 months until age 7 years and annually thereafter. In 
contrast, it was recommended that individuals with MCAP receive an annual abdominal 
ultrasound in all age groups [Lapunzina, 2005]. The American College of Medical Genetics 
practice guidelines for Wilms tumor screening in patients with isolated hemihyperplasia suggest 
abdominal ultrasound every 3 months until age 7 years [Clericuzio and Martin, 2009]. No 
abdominal ultrasound was recommended for individuals with Klippel-Trenaunay syndrome, 
based on Green et al.’s [2004] review of 115 patients with Klippel-Trenaunay who did not 
develop Wilms tumor and a study cohort of 8614 individuals with Wilms tumor, none of which 
had Klippel-Trenaunay. While there was one report each of bilateral Wilms tumor [Ehrich et al., 
1979] and bilateral nephroblastomatosis [Mankad et al., 1974] in individuals with Klippel-
Trenaunay syndrome, no recent reports of this association have been published. Importantly, 
these screening recommendations [Green et al., 2004; Lapunzina 2005] were published before 
the molecular characterization of Klippel-Trenaunay syndrome, and the clinical diagnosis of 
Klippel-Trenaunay syndrome is not always consistently defined, making it difficult to determine 
whether reported individuals actually had PROS or another overlapping disorder. Some patients 
with hemihyperplasia have an underlying somatic PIK3CA mutation and their increased risk for 
Wilms tumor, and possibly other embryonal tumors, may be at least partially accounted for by 
the PIK3CA mutation. Given the prevalence of PIK3CA mutations affecting codon 1047 in 
cancer, a critical consideration is whether patients with these particular mutations are at 
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increased risk of Wilms tumors. Including the cases reported here, four individuals with 
documented PIK3CA mutations and Wilms tumor or nephroblastomatosis were reported. The 
combined number of patients with documented PIK3CA mutations in the literature as 
calculated in Table II and after adding Patient 1 reported here is 258.  Considering 
ascertainment bias for the Patient 1 in this report it is likely that the risk for Wilms tumor or 
nephroblastomatosis in individuals with PIK3CA mutations is less than the calculated 4/258 or 
1.6%. While this risk is increased compared to the general population, it does not meet the 2-
5% risk suggested by Scott et al. [2006b] in order to warrant screening studies. However, in light 
of the clearly increased risk and the variable preferences of families and medical care providers 
in different care environments, we consider screening by ultrasound appropriate, similar to the 
recommendations for hemihyperplasia [Clericuzio and Martin, 2009], as indicated in Table III. 
Because many individuals with PROS have overgrowth, the screening guidelines for 
hemihyperplasia [Clericuzio and Martin, 2009] would be applied prior to the identification of a 
PIK3CA mutation.   
 Three patients with PROS and Wilms tumor or nephroblastomatosis had somatic 
mutations affecting PIK3CA codon 1047, which is associated with oncogenicity in isolated 
cancers. Both patients described here in more detail had extensive overgrowth involving the 
legs and trunk. Although this evidence is not sufficient to demonstrate high risk, it would be 
prudent to consider serial abdominal ultrasounds in patients with a somatic PIK3CA mutation 
similar to the recommendations for isolated hemihyperplasia and Beckwith–Wiedemann 
syndrome. More longitudinal data including clinical examination and regular screening studies 
are needed on patients with PROS due to different PIK3CA mutations, in order to accurately 
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determine risk of tumorigenesis. Screening recommendations may then possibly be stratified 
based on the specific mutation or the clinical presentation. 
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Legends: 
Figure 1:  Ultrasound of Patient 1 obtained at age 9 months, showing multiple hypoechoic, 
avascular right renal masses in the lower pole and interpolar region (a); contrast enhanced CT 
scans at age 9 months (b) and 12 months (c) show well-defined low attenuation lesions 
enlarging in size in the hypertrophied right kidney. The left kidney is atrophied. (c) MRI 
demonstrates well-defined lesions with mild heterogeneous internal enhancement. 
Figure 2:  Patient 1’s MRI obtained at age 7 years showed (A) a prominent right paraspinal fatty 
mass involving erector spinae musculature with anterior displacement of the right L3 exiting 
nerve root implying fat infiltration into the right L3-L4 neural foramen; increased diameter of 
the right psoas, thigh and calf musculature compared to the left (not shown) with enhancing 
lesions in the right psoas (B), vastus lateralis and medial right thigh musculature (C), and in the 
peroneus brevis (D). 
Figure 3: (A) Patient 1’s back at age 7 years, showing protrusion from lipoma over right lower 
back, (B, C) Patient 1’s legs note overgrowth of right leg, most obvious in the right thigh. 
Figure 4: Patient 2 at age 10 years, frontal view (A), showing reduced subcutaneous fat in her 
face, arms and chest, and lipomatous overgrowth of her left>right abdomen, right leg and left 
ankle, (B) back view, (C) closer view of her legs with overgrowth of right leg s/p right Syme 
amputation and lipomatous mass of her medial left ankle, (D) Closer view of her abdomen with 
masses involving the right upper abdomen, and left mid- to lower abdomen. 
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Table I:  Phenotypic and Molecular Findings in Individuals with Somatic PIK3CA Mutation and Nephroblastomatosis or Wilms Tumor 
 
 Patient 1 Patient 2  [Patient 23 in 
Keppler-Noreuil et al., 2014] 
Patient 3 
[CL 2 in Kurek et al., 2012] 
Patient 4 
[CL29 in Luks et al., 2015] 
PIK3CA mutation p.His1047Arg p.His1047Leu p.His1047Arg p.Asn345Lys 
mosaic yes yes yes yes 
Mutation 
distribution 
Blood 0% 
Psoas muscle 12.9-15.7 % 
Thigh mass 21.4-24.8% 
Blood 0% 
Left leg adipose & skin 3-4% 
Saliva 0% 
Debulked tissue 20% 
314/837 reads from affected 
tissue 
Sex Male Female Female Female 
Onset of 
symptoms 
Birth Birth Birth Not listed 
Age at last 
evaluation 
7 years 10 years Image shown age 18 months 3 years; patient died 
Original clinical 
diagnosis 
Hemihyperplasia Fibroadipose hyperplasia CLOVES  CLOVES 
Asymmetric 
overgrowth 
Yes Yes Yes Yes 
 
Area affected with 
overgrowth 
Right leg Right foot, leg, buttock; Left 
ankle, abdomen 
Legs, feet Macrodactyly, wide hands/feet, 
leg length discrepancy 
Fibroadipose 
overgrowth 
yes yes yes Not listed 
Area with 
lipomata 
Right lower back, right leg Left thigh; Right buttock, leg, 
foot, abdomen 
Trunk, limbs Torso, extremities 
Skin findings Hypopigmented lesion Pigmented nevus None listed Capillary malformation/ 
lymphatic malformation 
Renal findings Concern for Wilms tumor 
on imaging studies 
Concern for Wilms tumor on 
imaging studies 
Hypoplastic left kidney and 
Wilms tumor 
Renal agenesis/hypoplasia 
and Wilms tumor 
Histology of renal 
lesion 
Post treatment biopsy 
unable to differentiate 
between Wilms tumor and 
nephrogenic rests 
Bilateral adenomatous 
nephrogenic rests 
Not listed Not listed 
Treatment Chemotherapy Partial bilateral 
nephrectomy, chemotherapy 
Not listed Not listed 
Outcome of renal 
lesion 
Stable after chemotherapy Stable after chemotherapy Not listed Not listed 
Other  Lipohypoplasia upper torso, 
arms and face 
Polydactyly  Patient died, no further 
information listed 
 
Legend: CLOVES; Congenital lipomatous overgrowth with vascular, epidermal and skeletal anomalies 
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Table II: Wilms Tumor or Nephroblastomatosis in Cohorts of Patients with Somatic PIK3CA Mutations 
PIK3CA amino 
acid change 
Seattle 
cohort 
Cambridge 
cohort 
Keppler-
Noreuil et 
al. [2014] 
Luks et al., 
[2015] 
Table II 
Combined 
number of 
individuals 
Wilms tumor or 
nephroblastoma
tosis 
 N=86 N=73 N=35 N=73 257 **  
E81K 1 2   3  
R88Q 2 1   3  
R93Q 1 1   2  
R93W 1 1   2  
P104L 1 1   2  
G106V 1    1  
E110del 4 1   5  
G118D   1   1  
N345K    1 1 1 
N345T 1    1  
V346_347_Ins_K  1   1  
D350G  1   1  
D350N 1    1  
G364R 1 1   2  
E365K 1    1  
C378Y 6    6  
E418K  1   1  
C420R  2 1 7 10  
P449T 1 1   2  
H450R    1 1  
E453del 2 1   3  
E453K 4 1   5  
P471L  1   1  
E542K 2 8 3 13 26  
E545K 1 7 4* 23 34  
E545D 1    1  
E545G    1   
Q546K    1 1  
Q546R  1   1  
C604R  1   1  
E726K 13 7   20  
G914R 14 2   16  
D939G 1    1  
E970K 1    1  
Y1021C 1    1  
Y1021H 1    1  
T1025A 2 1  1 4  
A1035V 3    3  
A1035T 2    2  
M1043I 7 1   8  
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M1043V  1   1  
N1044Y  1   1  
H1047L  8 8* 6 17 1 (Patient 2) 
H1047Y 4    4  
H1047R 2 16 19* 18 51  
G1049R  1   1  
G1049S 2    2  
X1069W 2    2  
Wilms tumor or 
nephroblastomat
osis 
0 0 1 1   
 *Includes # patients from Cambridge cohort: 1 E545K, 5 H1047L, 4 H1047R. These patients have had 
follow up screening in the Cambridge cohort. 
** This is less than the cohorts combined because 10 patients were included in Keppler-Noreuil et al. 
[2014] and in the Cambridge cohort. 
 
Page 29 of 34
John Wiley & Sons, Inc.
American Journal of Medical Genetics: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Table III: Imaging Recommendations for Patients with PIK3CA-Related Overgrowth Spectrum (PROS) 
Organ 
system  
Concern or indication Suggested 
imaging study 
Timing of initial 
imaging study 
Timing of 
subsequent 
imaging studies 
Brain, 
Facial 
Ventriculomegaly, 
hydrocephalus, 
Chiari  
malformation/cerebellar 
tonsillar ectopia, cortical 
brain malformations 
(polymicrogyria) 
Brain MRI 
without 
contrast 
At diagnosis, if 
there is 
macrocephaly 
(OFC > 2 SD), 
developmental 
delay , epilepsy, 
facial or skull 
involvement 
As indicated 
based on results 
of previous 
studies or when 
symptomatic 
Spinal 
canal 
Tethered cord, 
Syringomyelia, 
Lipomeningocele 
Ultrasound in 
infant; MRI 
thereafter 
At diagnosis if 
truncal 
involvement 
present 
As indicated 
based on results 
of previous 
studies or when 
symptomatic 
Spine Scoliosis Spine  
radiographs 
At presentation 
if spinal 
asymmetry or 
truncal 
overgrowth is 
noted 
As indicated 
based on results 
of previous 
studies or when 
new onset 
scoliosis is 
suspected 
Trunk For truncal overgrowth, 
scoliosis, lymphatic or 
vascular malformations 
Whole body 
MRI, consider 
contrast as 
needed 
Infants at 12 
months (due to 
need for 
sedation); for 
older individuals 
at diagnosis 
As indicated 
based on results 
of previous 
studies or when 
symptomatic 
Extremitie
s 
Overgrowth, asymmetry, 
lymphatic or vascular 
malformations, 
thromboembolism 
Radiographs, 
MRI, 
Consider 
Doppler 
ultrasounds of 
involved arms, 
legs or both 
At diagnosis of 
overgrowth 
affecting 
extremities 
As indicated 
based on results 
of previous study; 
to monitor 
progression of 
overgrowth or to 
plan surgery 
Kidneys Enlargement, tumor 
(Nephroblastomatosis or 
Wilms tumor),   
Renal 
ultrasound  
At diagnosis  Repeat every 3-4 
months until age 
8 years  
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Figure 1:  Ultrasound of Patient 1 obtained at age 9 months, showing multiple hypoechoic, avascular right 
renal masses in the lower pole and interpolar region (a); contrast enhanced CT scans at age 9 months (b) 
and 12 months (c) show well-defined low attenuation lesions enlarging in size in the hypertrophied right 
kidney. The left kidney is atrophied. (c) MRI demonstrates well defined lesions with mild heterogeneous 
internal enhancement.  
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Figure 2:  Patient 1’s MRI obtained at age 7 years showed (A) a prominent right paraspinal fatty mass 
involving erector spinae musculature with anterior displacement of the right L3 exciting nerve root implying 
fat infiltration into the right L3-L4 neural foramen; increased diameter of the right psoas, thigh and calf 
musculature compared to the left (not shown) with enhancing lesions in the right psoas (B), vastus lateralis 
and medial right thigh musculature (C), and in the peroneus brevis (D).  
254x190mm (96 x 96 DPI)  
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Figure 3: (A) Patient 1’s back at age 7 years, showing protrusion from lipoma over right lower back, (B, C) 
Patient 1’s legs note overgrowth of right leg, most obvious in the right thigh.  
254x190mm (96 x 96 DPI)  
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Figure 4: Patient 2 at age 10 years, frontal view (A), showing reduced subcutaneous fat in her face, arms 
and chest, and lipomatous overgrowth of her left>right abdomen, right leg and left ankle, (B) back view, (C) 
closer view of her legs with hemihyperplasia of right leg s/p Syme amputation of her right foot and 
lipomatous mass of her medial left ankle, (D) Closer view of her abdomen with masses involving the right 
upper abdomen, and left mid- to lower abdomen.  
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